Cancer Drug Gets Priority FDA Review After Trial Shows No Signs of Tumors
Summary
The FDA has given priority review to GSK’s cancer drug Jemperli after a trial showed it could clear rectal tumors for at least one year in many patients. This drug might change treatment by letting some patients avoid chemotherapy, radiation, and surgery, which are the usual but harsh treatments for this cancer.Key Facts
- Jemperli is being reviewed by the FDA with a decision expected by February 2027, but an earlier decision is possible.
- The review is based on the AZUR-1 trial, which tested Jemperli alone in patients with a specific type of rectal cancer (stage II/III dMMR/MSI-H).
- The trial showed no detectable cancer signs in a significant number of patients for at least 12 months.
- 154 patients participated, all receiving nine cycles of Jemperli over six months.
- The drug’s safety profile matches what was already known and is manageable.
- Traditional treatment includes chemotherapy, radiation, and surgery, which can cause serious long-term side effects.
- Jemperli could help some patients avoid these treatments and their harmful effects, improving quality of life.
- Avoiding surgery also means avoiding risks like needing a permanent colostomy bag, fertility loss, and other health complications.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
